#USA #Seattle #Clinical Trials #Atossa Therapeutics #Z-Endoxifen

Atossa Therapeutics Reports Positive Advancement in Q2 2026

On August 7, 2026, Atossa Therapeutics, Inc. (Nasdaq: ATOS), a company at the forefront of biopharmaceutical innovation, shared its financial results alongside key corporate updates for the second quarter ending June 30, 2026. The report details significant progress in research and clinical trials, particularly focused on their flagship product, (Z)-endoxifen.

Dr. Steven Quay, President and CEO of Atossa Therapeutics, highlighted the company’s commitment to advancing its innovative treatment options. The results from the second quarter have been promising, especially regarding (Z)-endoxifen’s applications in both pediatric rare diseases, such as Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome, as well as breast cancer, a significant area of unmet clinical need.

Key Highlights from the Quarter

Rare Disease Initiatives

Atossa made notable strides during the 2026 American Association for Cancer Research (AACR) Special Conference, presenting research on (Z)-endoxifen's dual mechanism of action. This involves modulating estrogen receptor signaling and PKC-β, a critical pathway in managing conditions like McCune-Albright Syndrome-associated Peripheral Precocious Puberty (MAS-PPP). The FDA has previously designated (Z)-endoxifen as a Rare Pediatric Disease treatment for MAS, reinforcing its potential in addressing these complex health challenges.

Oncology Developments

In addition to its pediatric focus, Atossa has been generating interest in the oncology space. Recent publications, including one in npj Breast Cancer, outlined the anti-cancer activity of (Z)-endoxifen and its related compounds in estrogen receptor-positive breast cancer. Results showed that several new chemical entities derived from (Z)-endoxifen exhibited significant anti-cancer properties, leading to attention for further exploration in clinical settings.

Atossa also showcased its ongoing Phase 2 clinical trial—EVANGELINE, which examines (Z)-endoxifen combined with goserelin as neoadjuvant therapy for premenopausal women with ER+/HER2- breast cancer. This study achieved full enrollment by the end of June 2026, marking a critical milestone in bringing innovative treatments to market.

Financial Performance Overview

The report indicated total operating expenses of $8.7 million for Q2 2026, with a slight decrease in R&D expenditures compared to the previous year. Specific adjustments in clinical and non-clinical trial expenses reflect the company's focused strategies in funding pipelines and advancing critical clinical trials.

Additionally, a registered direct offering allowed Atossa to secure up to $16.5 million, strengthening its financial position and potential to accelerate the development of (Z)-endoxifen. This funding will support clinical development programs further while addressing operational needs.

Looking Forward

Atossa’s commitment to addressing significant medical needs through innovative therapies is clear. The FDA’s Orphan Drug Designation for (Z)-endoxifen reflects the ongoing recognition of its potential in treating serious health conditions. Just as importantly, the encouraging preclinical and clinical data underscore the company's mission to enhance treatment options for patients facing tough health challenges.

In light of this solid second quarter, Atossa continues to push forward with its strategic goals, bolstered by promising new findings and ongoing studies. As it charts the course for the future, Atossa Therapeutics remains a pivotal player in advancing biopharmaceutical therapies that cater to both rare and common diseases alike.

For more information about Atossa Therapeutics and their innovative work, visit atossatherapeutics.com.